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Abstract
In a mouse model of established extrahepatic colo-
rectal metastasis, we analyzed whether stromal cell–
derived factor (SDF) 1 stimulates tumor cell migration
in vitro and angiogenesis and tumor growth in vivo.
METHODS: Using chemotaxis chambers, CT26.WT
colorectal tumor cell migration was studied under
stimulation with different concentrations of SDF-1. To
evaluate angiogenesis and tumor growth in vivo, green
fluorescent protein–transfected CT26.WT cells were
implanted in dorsal skinfold chambers of syngeneic
BALB/c mice. After 5 days, tumors were locally ex-
posed to SDF-1. Cell proliferation, tumor microvascu-
larization, and growth were studied during a further
9-day period using intravital fluorescence micros-
copy, histology, and immunohistochemistry. Tumors
exposed to PBS only served as controls. RESULTS:
In vitro, > 30% of unstimulated CT26.WT cells showed
expression of the SDF-1 receptor CXCR4. On chemo-
taxis assay, SDF-1 provoked a dose-dependent in-
crease in cell migration. In vivo, SDF-1 accelerated
neovascularization and induced a significant increase
in tumor growth. Capillaries of SDF-1–treated tumors
showed significant dilation. Of interest, SDF-1 treat-
ment was associated with a significantly increased
expression of proliferating cell nuclear antigen and a
downregulation of cleaved caspase-3. CONCLUSION:
Our study indicates that the CXC chemokine SDF-1
promotes tumor cell migration in vitro and tumor
growth of established extrahepatic metastasis in vivo
due to angiogenesis-dependent induction of tumor cell
proliferation and inhibition of apoptotic cell death.
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Introduction
Colorectal cancer is one of the leading causes of cancer-
related deaths among men and women worldwide. Death
usually results from uncontrolled metastatic disease. The liver
is the most common site of metastasis, and surgical resection
is the only option for curative treatment, reflected by a 5-year
overall survival rate of up to 58% [1–4]. In contrast, manifes-
tation of extrahepatic metastases has long been considered as
a contraindication to resection of hepatic lesions. Some recent
studies, however, showed promising 5-year survival rates of
f 30% after sequential resection of hepatic and extrahepatic
colorectal metastases [5–7].
The metastatic process consists of a series of individual
steps, which all are required to establish metastatic tumors [8,9].
Whereas chemokines and their receptors are known to be in-
volved in the ‘‘homing’’ of hematopoietic cells to specific organs
as a physiological mechanism [10], homing is also functional in
neoplastic cells [11]. Recent studies have shown that tumor
cells express patterns of chemokine receptors and that cor-
responding ligands are specifically expressed in organs to
which these cancers commonly metastasize. For example,
breast cancer cells and primary breast cancers have been
shown to express the chemokine receptor CXCR4, whereas
the specific ligand CXCL12, also known as stromal cell –
derived factor (SDF) 1, has been found at elevated levels in
lymph nodes, lung, liver, and bone marrow—organs that rep-
resent the first metastatic sites of breast cancer [12]. Others
also speculated on the involvement of CXCR4 in the metastatic
tumor growth of different types of malignancies, including co-
lorectal cancer [13–15]. As shown by Ottaiano et al. [15], the
lack of CXCR4 and vascular endothelial growth factor (VEGF)
expression in both primary tumors and metastases is a strong
prognostic factor for the disease-free survival of colorectal can-
cer patients [16].
Although several studies have indicated that the CXCR4
receptor may be involved in the metastatic process of colo-
rectal cancer, the functional role of SDF-1 has not been iden-
tified yet. With the use of a murine colon cancer model,
we therefore studied whether SDF-1 affects the process of
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angiogenesis and the tumor growth of established extrahe-
patic metastasis in vivo.
Materials and Methods
Tumor Cell Lines and Culture Conditions
The CT26 cell line is a N-nitroso-N-methylurethane–
induced undifferentiated adenocarcinoma of the colon, syn-
geneic with BALB/c mice. For our studies, the CT26.WT cell
line (ATCC CRL-2638; LGC Promochem GmbH, Wesel,
Germany) was grown in cell culture as a monolayer in RPMI
1640 medium with 2 mM L-glutamine (Sigma Aldrich Chemie
GmbH, Taufkirchen, Germany) supplemented with 10% fetal
calf serum (FCS Gold; PAA Laboratories GmbH, Co¨lbe,
Germany), 100 U/ml penicillin, and 100 mg/ml streptomycin
(PAA Laboratories GmbH). The cells were incubated at 37jC
in a humidified atmosphere containing 5% CO2. With the
use of CLONfectin (Clontech, Palo Alto, CA), CT26.WT
cells were transfected with the enhanced green fluorescent
protein (GFP) expression vector pEGFP-N1 (Clontech), in
accordance with the manufacturer’s instructions [17]. GFP
transfection was performed by cloning. For individual in vitro
and in vivo experiments, only cells of the first three serial pas-
sages after cryostorage were used. On the day of implanta-
tion, CT26.WT-GFP cells were harvested from subconfluent
cultures (70–85%) by trypsinization (0.05% trypsin and
0.02% EDTA; PAA Laboratories GmbH) and washed twice in
phosphate-buffered saline (PBS) solution.
Flow Cytometric Analysis of CT26.WT Cells
FACScan (Becton Dickinson, Mountain View, CA) analy-
sis was performed to assess the expression of the chemo-
kine receptor CXCR4 on CT26.WTand CT26.WT-GFP cells
in triplicate. After trypsinization, the cells were fixed in 1 ml of
Cytofix/Cytoperm (BD Biosciences, Heidelberg, Germany)
for 20 minutes at 4jC, washed twice with Perm Wash (BD
Biosciences), and incubated at room temperature for 40 min-
utes with a polyclonal goat anti-mouse CXCR4 antibody
(Santa Cruz, Heidelberg, Germany) or an isotype-matched
control antibody (Dianova, Hamburg, Germany). A rabbit anti-
goat Cy3-conjugated antibody (1:25; Dianova) was used
for fluorescence labeling. To remove excess antibody, cells
were washed again and then maintained in 1% parafor-
maldehyde in PBS. A flow cytometer was calibrated with
fluorescent standard microbeads (CaliBRITE Beads; BD
Biosciences) for accurate instrument setting. Tumor cells
were selectively analyzed for their fluorescence properties
using the CellQuest data handling program (BD Biosci-
ences), with assessment of 5000 events per sample.
Cell Migration Assay
The migration capability of CT26.WT cells was assessed
using 24-well chemotaxis chambers and polyvinylpyrroli-
done-coated polycarbonate filters with an 8-mm pore size
(BD Falcon, Heidelberg, Germany). Chemotaxis assays were
performed in triplicate. The chemoattractant SDF-1 (recombi-
nant mouse SDF-1a/CXCL12, no. 460-SD; R&D Systems,
Wiesbaden, Germany), diluted in PBS with 0.1% BSA (Sigma
Aldrich Chemie GmbH), was added in concentrations of 0.1,
1, 10, 100, 200, and 400 nM to 700 ml of RPMI 1640medium in
lower wells. PBS with 0.1% BSA alone served as control. Five
hundred microliters of a cell suspension containing 1  105
cells in RPMI 1640 was added to each of the upper wells.
Then the chamber was incubated for 24 hours at 37jC in a
humidified atmosphere with 5% CO2. After incubation, non-
migrated cells were removed from the upper surface of the
filters, and migrated cells, which are adherent to the lower
surface, were fixed with methanol and stained with Dade Diff-
Quick (Dade Diagnostika GmbH, Mu¨nchen, Germany). The
number of these migrated cells was counted in 10 high-power
microscopic fields. In addition, the cells that had migrated into
the lower wells were collected and counted by FACScan flow
cytometry. Migrated cells that are adherent to the lower
surface of the filters are expressed as the number of cells
per 10 high-power fields; cells that had migrated to the lower
wells are expressed as the number of cells per well.
Animals
Experiments were performed after approval by the local
governmental ethics committee and conformed to the United
Kingdom Coordinating Committee on Cancer Research
Guidelines for the Welfare of Animals in Experimental Neo-
plasia (as described in 1998 in Br J Cancer 77, 1–10) and
the Guide for the Care and Use of Laboratory Animals (Insti-
tute of LaboratoryAnimalResources,National ResearchCoun-
cil; NIH Guide, Vol. 25, No. 28, 1996). Twelve- to 16-week-old
female BALB/c mice (Charles River Laboratories GmbH,
Sulzfeld, Germany) with a body weight of 18 to 22 g were
used. The animals were housed in single cages at room
temperature (22–24jC) and at relative humidity (60–65%)
with a 12-hour light/dark cycle environment. The mice were
allowed free access to drinking water and standard laboratory
chow (Altromin, Lage, Germany).
Experimental Model
For operative procedures, animals were anesthetized
with an intraperitoneal injection of 90 mg/kg body weight
ketamine (Ketavet; Parke Davis, Freiburg, Germany) and
20 mg/kg body weight xylazine (Rompun; Bayer, Leverkusen,
Germany). To allow repetitive analyses of the microcirculation
of growing tumors, the dorsal skinfold chamber model was
used for intravital microscopy, as previously described in de-
tail [18]. The chamber consists of two symmetrical titanium
frames (weight, 3.2 g), which were positioned to sandwich
the extended double layer of the dorsal skin. One layer was
completely removed in a circular area 15 mm in diameter. The
remaining layers, consisting of the epidermis, subcutaneous
tissue, and striated skin muscle, were covered with a glass
coverslip incorporated into one of the titanium frames [19].
The animals tolerated the chambers well and showed no signs
of discomfort or changes in sleeping and feeding habits. After
a 48-hour recovery period, the coverslip of the chamber was
temporarily removed, and 1  105 cells were implanted onto
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the surface of the striated muscle tissue within the chamber.
Directly after cell implantation, the chamber tissue was cov-
ered again with the coverslip [20].
Experimental Protocol
Sixteen animals received tumor cell implantation. After
5 days (day 0), the animals were assigned to two different
groups. The dorsal skinfold chamber was opened, and SDF-1
was locally applied (SDF-1; n = 8). The concentration was
100 nM in the final preparation. This concentration was di-
rectly exposed to the tissue within the dorsal skinfold cham-
ber. Accordingly, this was also the concentration in the skinfold
chamber at the time of treatment. Animals that received only
PBS served as controls (Control; n = 8). All animals underwent
repetitive intravital microscopic analyses directly before—as
well as 2, 4, 7, and 9 days after—SDF-1 exposure. At the end
of the experiment, the chamber with the tumor tissue was
harvested for histology and immunohistochemistry.
Intravital Fluorescence Microscopy
Intravital fluorescence microscopy was performed with
epi-illumination technique using a modified Zeiss Axio-Tech
microscope (Zeiss, Oberkochen, Germany) with a 100-W
HBO mercury lamp. Microscopic images were monitored by
a charge-coupled device video camera (FK 6990, COHU;
Prospective Measurements, Inc., San Diego, CA) and were
transferred to a video system (VO-5800 PS; Sony, Mu¨nchen,
Germany) for subsequent off-line analysis. Tumor size, growth
kinetics, and neovascularization were analyzed using blue light
epi-illumination (excitation wavelength, 450–490 nm; emission
wavelength, > 520 nm) [21].
Microcirculation Analysis
Microcirculatory parameters were assessed off-line by
a frame-to-frame analysis of videotaped images using a
computer-assisted image analysis system (CapImage; Zeintl
Software, Heidelberg, Germany). Data analysis was performed
by examiners blinded to the treatment.
The fluorescent labeling of tumor cells allowed precise
delineation of the tumor from the surrounding unaffected host
tissue. At each observation time point, the surface of the fluo-
rescently labeled tumor mass within the chamber was first
scanned for determination of tumor size (expressed as tumor
area in square millimeters). Next, eight regions of interest
(ROI) were randomly chosen within the tumor margin. In
these ROI, the onset of neovascularization (i.e., develop-
ment of angiogenic buds, sprouts, and blood vessels) was
documented and scored from 0 to 8, where 0 = neovascula-
rization in none of the ROI and 8 = neovascularization in all
of the ROI [22]. The functional capillary density (cm/cm2) of
the tumor microvasculature, defined as the length of red
blood cell–perfused capillaries per observation area [23],
was analyzed within the eight ROI of the tumor margin and
within four additional ROI of the tumor center. Diameters
of the newly formed tumor microvessels were measured
perpendicularly to the vessel path and are expressed in
micrometers [17].
Histology and Immunohistochemistry
At the end of the experiments (day 9), the tumor and adja-
cent host tissue were harvested. For light microscopy, formalin-
fixed biopsies were embedded in paraffin. Five-micrometer
sections were cut and stained with hematoxylin–eosin for rou-
tine histology, in accordance with standard procedures. Tumor
cell invasion of the muscular layer was measured and ex-
pressed as a percentage of the length of the tumor basis [24].
To study cell proliferation and apoptotic cell death, prolif-
erating cell nuclear antigen (PCNA) and cleaved caspase-3
were stained using indirect immunoperoxidase techniques.
Therefore, deparaffinized sections were incubated with 3%
H2O2 and 2% goat normal serum to block endogenous
peroxidases and unspecific binding sites. A monoclonal
mouse anti-pan PCNA antibody (PC10, 1:50; DakoCytoma-
tion, Hamburg, Germany) and a polyclonal rabbit anti-mouse
cleaved caspase-3 antibody (Asp175, 1:50; Cell Signaling
Technology, Frankfurt, Germany) were used as primary anti-
bodies [25]. The cleaved caspase-3 antibody detects endog-
enous levels only of the short fragment (17/19 kDa) of activated
caspase-3, but not full-length caspase-3. Biotinylated goat
anti-mouse and goat–rabbit Ig antibodies were used as sec-
ondary antibodies for streptavidin–biotin complex peroxi-
dase staining (1:200, LSAB 2 System HRP; DakoCytomation).
3,3V-Diaminobenzidine (DakoCytomation) was used as chromo-
gen. Sections were counterstained with Mayer hemalum stain
and examined by light microscopy.
To assess the expression of the chemokine receptor
CXCR4, tumor slices were embedded in Tissue FreezingMe-
dium (Jung; Leica Microsystems, Nussloch, Germany) for
immunohistochemistry, snap-frozen in liquid nitrogen, and
stored at 80jC. Five-micrometer cryostat sections were
cut, fixed in 4jC cold acetone for 5 seconds and in 4% for-
malin for 10 minutes, and blocked with 2% normal donkey
serum. Then tissue sections were incubated with a poly-
clonal goat anti-mouse CXCR4 antibody (1:10; Santa
Cruz). A donkey anti-goat IgG HRP-conjugated antibody
(1:500; Amersham, Freiburg, Germany) was used as sec-
ondary antibody. 3,3V-Diaminobenzidine was used as chro-
mogen. Sections were counterstained with Mayer hemalum
stain and examined by light microscopy.
As a negative control, additional slices from each speci-
men were exposed to appropriate IgG isotype–matched
antibody (Sigma Aldrich Chemie GmbH), instead of the pri-
mary antibody, under the same conditions to determine the
specificity of antibody binding. All of the control stainings
were found to be negative.
Statistical Analysis
All values are expressed as mean ± SEM. After proving
the assumption of normality and homogeneity of variance
across groups, the groups studied were compared by a
nested design, including analysis of variance and post hoc
comparison with correction of a error according to Bonferroni
probabilities to compensate for multiple comparisons. Sta-
tistical significance was set at P < .05. Statistical analyses
were performed using the software package SigmaStat
(SPSS, Inc., Chicago, IL).
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Results
In Vitro FACScan Analysis and Migration Assay
FACScan analysis demonstrated that 31.5 ± 2.5% of
CT26.WT cells were CXCR4 receptor–positive (Figure 1A).
After transfection with the enhanced GFP expression vector
pEGFP-N1, CT26.WT-GFP cells showed a comparable ex-
pression of CXCR4 (32.2 ± 4.3%) (Figure 1B). In cell culture,
both cell lines had similar growth characteristics during the
7-day observation period (Figure 1C).
Migration assay indicated that only a few cells migrated
under control conditions (i.e., with PBS stimulation; Figure 2).
SDF-1 at a dose of 0.1 nM induced a 3.4-fold increase in
cell migration at polycarbonate filters. With 1 nM SDF-1, this
migration was most pronounced, as indicated by a 4.3-fold
increase compared to controls (Figure 2A). Notably, a further
increase in SDF-1 concentration resulted in a markedly de-
creased number of cells that were found to be adherent to
the lower surface of the filters of the migration chambers.
Analysis of the number of cells that had migrated through the
filter to the lower wells indicated a 2-fold to 6-fold increase
after low-dose SDF-1 stimulation (0.1–100 nM), whereas
higher doses of 200 and 400 nM resulted in an exponential
increase (16-fold to 17-fold) when compared with PBS con-
trols (Figure 2B).
Tumor Growth
The general conditions of all BALB/c mice were not
affected by the implantation of the dorsal skinfold chamber
and tumor cell implantation. All animals had an uneventful
postoperative recovery, and they tolerated well intravital
fluorescence microscopic observations during the 14-day
period. The take rate of colorectal CT26.WT-GFP cells in
the dorsal skinfold chamber was 100%. Intravital fluores-
cence microscopy showed progressive tumor growth dur-
ing the entire observation period in both groups (Figure 3,
A and B). Local application of SDF-1 on day 0 provoked a
significant acceleration of tumor growth when compared with
that measured in PBS controls. This was indicated by an in-
creased tumor area at late time points during the 9 days of
observation (Figure 3C).
Neovascularization
In both groups, analysis revealed a 40% to 50% neo-
vascularization of the ROI of newly developed microvessels
within the margin of the tumors on day 2. Of interest, on day
4, this ratio amounted tof 65% in controls, but was found to
increase to > 95% after SDF-1 treatment (Figure 4C). At the
end of the experiments, all ROI of both groups demonstrated
new vessel formation within the tumor margin.
The vascular networks of the tumors were characterized
by newly developed, chaotically arranged capillaries. The
capillary density of these networks did not differ between
tumor margin and tumor center (data not shown). Of interest,
however, SDF-1–treated tumors had developed a higher
density of newly formed tumor vessels within the tumor mar-
gin 4 days after SDF-1 application when compared to sham
controls (Figure 4D). At the end of the experiment, the tu-
mors of both groups showed a similar capillary density within
their margins and centers.
Because neovascularization is regularly associated with
vasodilation due to the action of VEGF, we analyzed capil-
lary diameters within tumor vascular networks. Directly
after SDF-1 treatment, newly formed capillaries at the tumor
center showed significant (P < .05) dilation when compared
with that of controls on days 2 and 4 (Figure 5). Capillary
diameters of the tumor margins (data not shown) showed the
same characteristics when compared to that observed in
tumor centers.
Morphology, Proliferation, Apoptotic Cell Death,
and CXCR4 Expression
Hematoxylin–eosin staining of the tumors on day 9 after
SDF-1 exposure revealed solid extrahepatic growth within
the dorsal skinfold chamber. In parallel to the significantly
increased growth of the tumors after SDF-1 application,
Figure 1. FACScan analysis of CT26.WT (A and C; white squares) and
CT26.WT-GFP (B and D; black squares) cells demonstrating f 30% posi-
tively stained cells for the chemokine receptor CXCR4 (C and D). Isotype-
matched control antibody served as a negative control (A and B). Note that
there is no difference in CXCR4 expression between GFP-transfected and
nontransfected cells. The two cell lines showed comparable growth
characteristics during the 7-day observation period (E). Data are expressed
as mean ± SEM.
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demonstrated by an increased tumor area during the 9 days
of observation, quantitative analysis of histologic specimens
showed a more invasive tumor growth with muscle infiltration
after SDF-1 treatment. This was indicated by the infiltration
of 23.3 ± 9.5% of the tumor basis after SDF-1 exposure when
compared to 10.5 ± 6.3% in sham controls.
PCNA as an indicator of cell proliferation showed that
almost 40% of the tumor cells displayed positive staining in
controls (Figure 6, A and E ). Notably, the rate of PCNA-
positivecellswas found tohavesignificantly increased to>70%
after SDF-1 treatment (Figure 6, B and E ). This indicates an
increase in tumor cell proliferation directly mediated by SDF-1.
To study apoptotic cell death, cleaved caspase-3 products
were detected by immunohistochemistry. On day 9, a minor
fraction of positively stained cells could be observed within
the tumors (Figure 6, C and D). Of interest, quantitative anal-
ysis demonstrated a significantly (P < .05) lower fraction of
apoptotic cells after SDF-1 application when compared with
that of sham controls (Figure 6F ).
Discussion
The major findings of the present study are that SDF-1
promotes a dose-dependent migration of colorectal cancer
cells in vitro and tumor growth of solid metastasis in vivo. Of
interest, the in vivo stimulation of growth is most probably
induced by an angiogenesis-dependent induction of tumor
cell proliferation and inhibition of apoptotic cell death.
Whereas many chemokines bind to more than one re-
ceptor, and chemokine receptors generally bind more than
one chemokine, SDF-1 is still the only known ligand of CXCR4
[10,12]. In contrast, SDF-1 may bind not only to CXCR4
but also to CXCR7 [26]. SDF-1 induces the internalization
of CXCR4-promoting calcium mobilization and activation of
mitogen-activated protein kinase pathways, such as ERK-1/2,
phosphatidylinositol 3-kinase (PI 3-kinase), and protein kinase
B—kinases that have been implicated in cell migration, pro-
liferation, differentiation, and survival [27].
CXCR4 is thought to facilitate the interaction between
tumor cells and endothelial cells by activating rolling, integrin
function, arrest, and transendothelial migration of tumor cells
[28,29]. Although never proven in vivo, SDF-1 has been
thought to direct the intratissue localization of tumor cells
and to induce metastasis through direct effects on tumor cell
migration [30,31], as recently suggested for the monocyte
chemoattractant protein-1 CCL2 [32]. Using a non–small cell
lung cancer cell line in vitro, Phillips et al. [33] have demon-
strated a directional movement in response to a CXCL12–
CXCR4 chemotactic gradient, with the highest amounts of
migrated cells at a concentration of 10 ng/ml SDF-1. In line
with others [34–36], our in vitro assay also showed a dose-
dependent increase in tumor cell migration in response to
SDF-1. This further supports an involvement of SDF-1 in
metastatic tumor growth.
Figure 2. Cell migration assay consisting of a chemotaxis chamber and polyvinylpyrrolidone-coated polycarbonate filters with an 8-m pore size. Note that only a
few cells migrate under control conditions (control in A and B), whereas stimulation with a low dose (1 nM) of SDF-1 exerts the most pronounced increase in the
fraction of migrated cells adhering to the lower surface of the filters (A). In contrast, analysis of cell migration to the lower wells (B) shows a dose-dependent
increase after SDF-1 exposure. Data are expressed as mean ± SEM.
Figure 3. Time course of tumor growth in dorsal skinfold chambers after
implantation of CT26.WT-GFP cells in BALB/c mice. Day 9 stereomicroscopy
photomicrographs of representative tumors from mice that underwent, on day
0, local sham treatment (A) and exposure to 100 nM SDF-1 (B). Quantitative
analysis of the tumor area over time (C) shows progressive tumor growth in
both sham-treated controls (white circles) and animals that underwent SDF-1
treatment (black squares). Note, however, that tumor growth after SDF-1
application is significantly increased compared to PBS controls. Data are
expressed as mean ± SEM. *P < .05 vs PBS control. (A and B) Original
magnification, 4.
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A considerable number of previous studies have demon-
strated that an overexpression of CXCR4 on tumor cells is
associated with an increased tumor growth and a cancerous
phenotype [28,36–38], and that neutralization of CXCR4
suppresses growth in vivo [13,14]. These data indicate a
role for CXCR4 in tumor growth and metastasis; however,
they did not prove the function of SDF-1. In fact, there is only
sparse information on SDF-1 function in carcinogenesis
in vivo. Orimo et al. [39] have demonstrated the inhibition
of growth breast cancer cells in vivo by blockade of SDF-1. In
contrast, Phillips et al. [33] have failed to demonstrate that
neutralization of SDF-1 affects the size of primary non–small
cell lung cancer tumors at orthotopic or heterotopic sites.
Beside this controversy, there is no information on how direct
SDF-1 exposure influences tumor growth in vivo. The results
of the present study now demonstrate for the first time that
SDF-1 application is capable of directly increasing tumor
growth in vivo.
The mechanisms on how SDF-1 stimulates the outgrowth
of established tumors and metastasis are not fully under-
stood yet. There is some evidence that the chemokine
influences both cell proliferation and apoptotic cell death. In
a previous study, we have demonstrated that SDF-1 stimu-
lation provokes nuclear translocation of both ERK-2, an ac-
cepted activator of transcription, and protein kinase B [27].
Others have further shown that SDF-1 induces mitogen-
activated protein kinases and Akt activation, however, with-
out influencing Fas ligand– induced apoptosis [35]. The
SDF-1/CXCR4 pathway influences the growth of invasive
and micrometastatic tumor cells [14], reflecting downstream
signaling through the antiapoptotic AKT kinase [40] and the
lipid kinase PI 3-kinase [41]. Several lines of evidence sug-
gest that PI 3-kinase–mediated activation of protein kinase
B inhibits apoptosis and promotes cell survival [42–44]. Fur-
thermore, ERK-1/2 and Akt activation mediate antiapoptotic
pathways and increase cell proliferation [40,42]. Although all
Figure 4. Time course of neovascularization and functional capillary density of CT26.WT-GFP tumors in dorsal skinfold chambers as determined by intravital
fluorescence microscopy. Fluorescence microscopic images display the capillary network in the tumor margins of a control animal (A) and an SDF-1– treated
animal (B) on day 4. Analysis of the onset of neovascularization, expressed as a score from 0 to 8, (C) in control tumors (white circles) and SDF-1– treated tumors
(black squares) showed accelerated angiogenesis after SDF-1 treatment compared to PBS controls (C). Analysis of capillary density within the tumor margin
confirms an acceleration of vascularization due to SDF-1 treatment, as indicated by an increased capillary density on day 4 after chemokine exposure (D). Data are
expressed as mean ± SEM. *P < .05 vs PBS control. (A and B) Original magnification, 40.
Figure 5. Time course of capillary diameters of newly formed tumor vessels
as determined by intravital fluorescence microscopy. Fluorescence micro-
scopic images display the capillary network in the tumor center of a PBS
control animal (A) and an SDF-1– treated animal (B) on day 9 after treatment
induction. Quantitative analysis showed a significantly greater capillary
diameter after SDF-1 exposure (black squares) when compared to PBS
controls (white circles) (C). Data are expressed as mean ± SEM. *P < .05 vs
PBS control. (A and B) Original magnification, 80.
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studies on the role of the SDF-1/CXCR4 pathway in cell pro-
liferation and apoptotic cell death have been performed in
in vitro setups [35,36], we herein demonstrate for the first
time that SDF-1 is capable of stimulating tumor cell prolifer-
ation and of inhibiting apoptotic cell death also in vivo, and
that these are most probably the cause of the observed
chemokine-mediated stimulation of tumor growth.
Neoangiogenesis in tumors is determined by an imbal-
ance in the overexpression of the proangiogenic factors and
inhibiting factors of angiogenesis. CXC chemokines with a
highly conserved three-amino-acid motif (Glu–Leu–Arg;
ELR motif; ELR+), including CXCL1–3 and CXCL5–8 (e.g.,
MIP-2 and IL-8), are potent promoters, whereas CXC che-
mokines lacking the ELRmotif (ELR), including CXCL4, are
potent inhibitors of angiogenesis [45]. Although SDF-1 is not
an ELR+ CXC chemokine, it is supposed to be involved in
mediating angiogenesis by interacting with its receptor
CXCR4 [46,47]. The SDF-1/CXCR4 pathway has been
shown to be essential for development because mice defi-
cient for CXCR4 or its ligand SDF-1 die perinatally due to
major defects of the vascular system [48].
Using prostate tumors, Darash-Yahana et al. [28] have
demonstrated a 4.5-fold increase in the number of blood
vessels in tumors overexpressing CXCR4 and concluded
that a high expression of this chemokine receptor acceler-
ates angiogenesis by increasing the secretion of VEGF.
These results are supported by the fact that neutralization
of CXCR4 successfully inhibits the formation of new blood
vessels [13,28]. In vitro studies have further shown that
CXCR4 mediates tumor cell migration toward SDF-1 and
that this migration is dependent on autocrine VEGF expres-
sion [46]. Of interest, SDF-1 may influence the expression
of VEGF. Brand et al. [35] have demonstrated in the colo-
rectal cancer cell line HT-29 that SDF-1 stimulation induces
an 8-fold upregulation of VEGF mRNA expression and a
5.8-fold increase in VEGF protein levels.
These findings have been confirmed by Yang et al. [49] in
glioblastoma cell lines, demonstrating that the expression of
functional CXCR4 correlates with malignant phenotype and
that stimulation with SDF-1 contributes to the production of
VEGF in vitro. It has been speculated that VEGF and SDF-1
may synergistically induce tumor angiogenesis [50]. Through
the upregulation of CXCR4 on vascular endothelial cells,
VEGF synergizes SDF-1–mediated vascular endothelial cell
migration and expansion. Carr et al. [51] have demonstrated
in the in vitro aortic ring model that despite the absence of
Figure 6. PCNA (A and B) and cleaved caspase-3 (C and D) immunohistochemistry in CT26.WT-GFP tumors on day 9 after PBS (control; A and C) and SDF-1
treatment (SDF-1; B and D). Quantitative analysis of the number of PCNA-positive cells (expressed as a percentage of all cells) revealed significantly more
positively stained cells in SDF-1– treated tumors when compared with tumors of controls (E). Analysis of cleaved caspase-3 expression (expressed as a
percentage of all cells) showed a significantly reduced number of apoptotic cells after SDF-1 treatment when compared to PBS controls (F). Data are expressed as
mean ± SEM. *P < .05 vs PBS control. (A–D) Original magnification, 175.
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circulating endothelial precursor cells, exogenous SDF-1
increases vascular sprouting. In parallel, Orimo et al. [39]
have shown with an indirect experimental approach that
carcinoma-associated fibroblasts, which secrete great
amounts of SDF-1, promote angiogenesis by recruiting en-
dothelial precursor cells. In these experiments, the role of
SDF-1 in angiogenesis was supported by the fact that in-
hibition of the CXC chemokine significantly reduced angio-
genic response [39]. These results are in contrast to those
reported by Phillips et al. [33], who have demonstrated that
blockade of SDF-1 did not influence the process of tumor
vascularization. In the present study, we demonstrate in a
direct experimental approach that exogenous application of
SDF-1 indeed affects the angiogenesis and vascularization
of colorectal tumors in vivo. However, SDF-1 did not induce
an overall increase in the number of newly formed blood
vessels, but specifically accelerated the process of blood
vessel formation. This action most probably involved an
increase in VEGF expression because SDF-1–treated tu-
mors showed a significant dilation of their blood vessels
compared to those of PBS-treated controls, which may be
caused by the well-known dilatory action of the growth factor.
In conclusion, we have demonstrated that the chemokine
SDF-1 promotes solid metastatic tumor growth by pro-
proliferative and antiapoptotic actions in an angiogenesis-
dependent manner. Our results therefore indicate that the
SDF-1/CXCR4 signaling pathway may be a promising target
for adjuvant antitumor therapy.
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